Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes ; volume:67 ; number:5 ; day:22 ; month:2 ; year:2024 ; pages:822-836 ; date:5.2024
Diabetologia ; 67, Heft 5 (22.2.2024), 822-836, 5.2024
- Creator
-
Cardoso, Pedro
Young, Katie G.
Nair, Anand T. N.
Hopkins, Rhian
McGovern, Andrew P.
Haider, Eram
Karunaratne, Piyumanga
Donnelly, Louise
Mateen, Bilal A.
Sattar, Naveed
Holman, Rury R.
Bowden, Jack
Hattersley, Andrew T.
Pearson, Ewan R.
Jones, Angus G.
Shields, Beverley M.
McKinley, Trevelyan J.
Dennis, John M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00125-024-06099-3
- URN
-
urn:nbn:de:101:1-2405212104444.948322369107
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cardoso, Pedro
- Young, Katie G.
- Nair, Anand T. N.
- Hopkins, Rhian
- McGovern, Andrew P.
- Haider, Eram
- Karunaratne, Piyumanga
- Donnelly, Louise
- Mateen, Bilal A.
- Sattar, Naveed
- Holman, Rury R.
- Bowden, Jack
- Hattersley, Andrew T.
- Pearson, Ewan R.
- Jones, Angus G.
- Shields, Beverley M.
- McKinley, Trevelyan J.
- Dennis, John M.
- SpringerLink (Online service)
Other Objects (12)
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care
Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
DURATION-8: SGLT2-Hemmer plus GLP-1-Agonist : „Traumpaar“ für die Kombinationstherapie?
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Potential implications of long-acting GLP-1 receptor agonists for critically ill
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care
Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
DURATION-8: SGLT2-Hemmer plus GLP-1-Agonist : „Traumpaar“ für die Kombinationstherapie?
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Potential implications of long-acting GLP-1 receptor agonists for critically ill
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care
Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
DURATION-8: SGLT2-Hemmer plus GLP-1-Agonist : „Traumpaar“ für die Kombinationstherapie?
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Potential implications of long-acting GLP-1 receptor agonists for critically ill